How Long Until Psychedelic Stocks Payoff?🍄🚀| MindMed (MNMD), Cybin (CYBN), Numinus (NUMI) and more

Who’s next in line to Uplist to the Nasdaq? Numinus? Cybin? FieldTrip? ALL of them??
Today, I’ll be covering an article by Jeff Neilson published on The Psychedelic Stock Watch. In this article, Jeff outlines several stocks as contenders for an uplisting.

* Cybin Inc (CAN:CYBN / US:CLXPF) : Cybin is also one of the more successful companies in raising capital, having raised ~CAD$88.8 million (US$70 million) since going public last November and as we have been repeating on this channel, capital is a very important factor for the successful continuation and advancement of clinical trials.

*Field Trip Health (CAN:FTRP / US:FTRPF) : Field Trip Health shares some similarities with Cybin as an uplisting prospect. It has raised even more capital than Cybin, in excess of US$100 million, including its recent CAD$95 million bought deal financing (US$76 million) and Field Trip has also a price target of CAD$8.50 price target from Stifel GMP to its February 2021 high of CAD$8.25.

*Numinus Wellness (CAN:NUMI / US:LKYSF) : Numinus Wellness actually has a stronger following among retail investors than either Cybin or Field Trip. It was second only to MindMed as the volume leader among psychedelic stocks in the 2020 rally. It was also the second-best performer among all of the leading stocks in that rally, generating a 10X return at its 2020 peak.

However, these are not the only psychedelic stocks to peak Jeff Neilson’s eye.
He also mentions:

Mind Cure Health (CAN:MCUR / US:MCURF)
Mydecine Innovations Group (CAN:MYCO / US:MYCOF)
Bright Minds Biosciences (CAN:DRUG / US:BMBIF)
Small Pharma Inc( it hasn’t even started public trading YET)

Timestamps:
0:00 – Intro
1:55 – Cybin ( CYBN / CXPF )
6:13 – Field Trip Health ( FTRP / FTRPF )
9:05 – Numinus Wellness ( NUMI / LKYSF )
11:35 – Mindcure Health
12:08 – Mydecine ( MYCO /MYCOF )
12:34 – Bright Minds Biosciences ( DRUG / BMBIF )
13:10 – Small Pharma Inc.

Link to the article in question: https://psychedelicstockwatch.com/psychedelic-stock-news/the-next-psychedelic-stock-to-uplist-on-the-nasdaq?fbclid=IwAR3CgezfqtNHk0U3_YX5LYHDU2Y34jEFSTdNVGVchsKgR4CdEj58Q-lYcwk
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Canacord: https://thetradingpriest.com/wp-content/uploads/2021/04/ResearchReport-1.pdf
Link to Numinus (NUMI): https://numinus.ca/
Link to Field Trip ( FTRP / FTRPF) : https://www.fieldtriphealth.com/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Cybin #Numi

In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.

In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.

From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.

Perhaps, psychedelics can treat mental health issues in general.

Perhaps, ketamine can be used to heal.

In the conversation, MDMA to treat addiction was also discussed.

Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.

With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.

From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.

#Psychedelics #Awakn #PsychedelicStocks

Results Are OUT! Finally we see that psilocybin is MORE EFFECTIVE in treating depression than the commonly used SSRIS. This study, run by the Imperial College of London is the FIRST MAJOR STUDY directly comparing SSRI’s with psilocybin, the predominant method of treatment.
The data was released on the 14th of April. So yes, this psilocybin trial treating depression CRUSHED SSRIS!
The study had 59 patients with Major Depressive Disorder, 30 of whom took 2 doses of Psilocybin 3 weeks apart, and 29 of whom took an SSRI, and the results will have MASSIVE IMPLICATIONS throughout the psychedelic investing world.
Though the study’s primary research objective which was purely by how much depression declined using the Quids SR 16 test, EVERY OTHER MEASUREMENT, such as using other measuring methods, decreases in Suicide ideation and percentage of patients in remission were secondary research objectives.

And again, every secondary research objective heavily FAVORED psilocybin.

This will be major news for companies like Compass Pathways (CMPS) and MindMed (MMED / MMEDF / MMQ)

Link to study: https://www.nejm.org/doi/suppl/10.1056/NEJMoa2032994/suppl_file/nejmoa2032994_appendix.pdf
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
​…
​
https://benzinga.grsm.io/thepsychedel
​…
​

General thoughts. We’ve been covering decriminalization and legalization efforts for almost two months now and EVERY WEEK, we see a new state or city starting to understand that psychedelics may be beneficial to society and may be able to treat mental illnesses such as depression, anxiety, ADHD, etc. On top of that, every week, we see study after study releasing promising results on the benefits of psychedelics to treat such mental maladies. If this is not proof that the SHROOM BOOM is real, what is? As more studies are released, it’ll only become more clear that psychedelics such as psilocybin, MDMA, DMT, LSD, etc may be able to disrupt a TRILLION dollar industry and us psychedelic investors might as well extract two-fold benefits : a. getting massive returns on investment and b. contributing to make the world a better place.

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​​​ ​#psilocybin​​​​ #shroomboom